Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

1 Oct 2022

Abstract excerpt

Low-dose human interleukin-2 (hIL-2) treatment is used clinically to treat autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive regulatory T cells (Tregs). However, off-target immune cell activation and short serum half-life limit the clinical potential of IL-2 treatment. Recent work showed that complexes comprising hIL-2 and the anti-hIL-2 antibody F5111 overcome these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Monoclonal and Polyclonal Antibodies Research
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36261022
DOI: 10.1016/j.celrep.2022.111478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protectionPMID 36261022Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunitySemantic proximity Read ↗

Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T cell responses during chronic viral infectionSemantic proximity Read ↗

Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacitySemantic proximity Read ↗

Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.Semantic proximity Read ↗

Potent antitumor activity of a designed interleukin-21 mimicSemantic proximity Read ↗

An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancerSemantic proximity Read ↗

An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice.Semantic proximity Read ↗

Dual Immune Checkpoint and Cytokine Receptor Modulation by an Engineered Human CTLA-4/IL-10 Bispecific Fusion ProteinSemantic proximity Read ↗

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1Semantic proximity Read ↗

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.Semantic proximity Read ↗

Insights into Cytokine–Receptor Interactions from Cytokine EngineeringSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.